Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-01-18
2011-12-06
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S311000, C514S314000, C544S363000, C546S134000, C546S135000
Reexamination Certificate
active
08071601
ABSTRACT:
The present invention relates to an adenosine A3receptor ligand of the general formula (I).
REFERENCES:
patent: 6969723 (2005-11-01), Aranyi et al.
patent: 0566226 (1993-10-01), None
patent: 1180514 (2002-02-01), None
patent: WO 98/43960 (1998-10-01), None
patent: WO 02/096879 (2002-12-01), None
Golub, T.R. et al., “Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring,” Science (1999), vol. 286, pp. 531-537.
Rimmer, J. et al., “Targeting adenosine receptors in the treatment of allergic rhinitis: a randomized, double-blind, placebo-controlled study,” Clinical and Experimental Allergy (2007), vol. 37, pp. 8-14.
Kreckler, Laura M. et al., “Adenosine Inhibits Tumor Necrosis Factor—αRelease from Mouse Peritoneal Macrophages via A2Aand A2Bbut Not the A3Adenosine Receptor,” The Journal of Pharmacology and Experimental Therapeutics (2006), vol. 317, pp. 172-180.
Gessi, Stefania et al., “The A3adenosine receptor: An enigmatic player in cell biology,” Pharmacology and Therapeutics (2008), vol. 117, pp. 123-140.
Nakamura, Kazuki et al., “Antitumor Effect of Cordycepin (3′-Deoxyadenosine) on Mouse Melanoma and Lung Carcinoma Cells Involves Adenosine A3Receptor Stimulation,” Anticancer Research (2006), vol. 26, pp. 43-47.
Burduliene, et al., “Chloroethyl derivatives of 2,5-diaminobenzoic acid,” Database Beilstein, Beilstein Institute for Organic Chemistry, XP 002299337 (1973), vol. 4, pp. 55-58.
Carboni, S., “Researches in the field of pyridine. I. 2-Amino-5-nitronicotinic acid,” Database Beilstein, Beilstein Institute for Organic Chemistry, XP 002299336 (1953), Abstract vol. 83, pp. 637-640.
Hynes, J.B. et al., “Improved Synthesis and Antitumor Evaluation of 5,8-dideazaisofolic Acid and Closely Related Analogues,” Journal of Medicinal Chemistry (1984), vol. 27, pp. 232-235.
Jakobsen, Palle et al., “Inhibitors of the tissue factor/factor Vlla-induced coagulation: synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3,1-benzoxazin-4-ones,” Bioorganic and Medicinal Chemistry (2000), vol. 8, pp. 2095-2103.
Chou, You-Ling et al., “Structure-Activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors,” Bioorganic and Medicinal Chemistry Letters (2003), vol. 13, pp. 507-511.
Chou, et al., Beilstein Abstract No. 9271163, 2003.
Aranyi Peter
Batori Sandor
Boer Kinga
Finet Michel
Gerber Katalin
Anderson Rebecca
Sanofi-Aventis
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Aminoquinoline derivatives and their use as adenosine A3... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Aminoquinoline derivatives and their use as adenosine A3..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aminoquinoline derivatives and their use as adenosine A3... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4268156